



The Cancer Institute at
St. Francis Hospital
The Heart Center

2015 Site-Specific Study: Female Breast Cancer, Stage I,

Joseph Pipala, MD, St Francis Dept of Oncology


An Assessment of Compliance with Evidence-Based Guidelines for Hormonal Therapy

St Francis Hospital diagnosed and/or treated 309 breast cancer cases in 2014. Of this population, there were 152 cases of AJCC Stage I female breast cancer. This Study is addressing those Stage I patients over age 70 who had hormone positive breast cancer. Therefore, this particular subset contained 40 patients.

The age range for the 40 patients was from 71-95 years of age with an average age of 79. The distribution for those patients between ages 71 and 79 was 22 and the remaining 18 patients were between ages 80-95.


The AJCC defines Stage I breast cancer invasive tumors as a size of ≤ 20 mm with no regional lymph node metastases or with micrometastases to the lymph nodes. The tumor sizes of ≤ 20 mm are sub-classified as "T1a, T1b or T1c".

As for the 40 patients evaluated for this Study, the "T" categories denoting tumor size contained 5 patients with T1a tumors (<5mm), 14 patients with T1b tumors measuring between 5mm and 10mm and 21 patients with T1c tumors sized >10mm but ≤ 20 mm. All patients had negative lymph nodes and none had micrometastases to their lymph nodes.



Evidence-based guidelines provided by the National Comprehensive Cancer Network (NCCN) and the National Quality Forum (NQF) recommend hormonal therapy for those patients with estrogen positive tumors. In keeping with the guidelines, 100% of the 40 patients were offered hormonal therapy as adjuvant treatment following their surgery for breast cancer. Given this Study's age criteria, the majority of patients were offered an aromatase inhibitor due to their post-menopausal status.

Upon closer evaluation, these 40 patients had the following hormonal treatment results: (33) of the (40) received hormonal therapy, (3) patients refused, and (4) patients did not receive therapy due to their contraindications to this medication (i.e...history of osteoporosis, liver or kidney abnormalities).



An evaluation of the 5-year overall survival rate for SFH AJCC Stage I breast cancer patients diagnosed from 2003-2008 revealed the following:

SFH (n=521 patients)	Stage I, 5-year survival rate=88%
----------------------	-----------------------------------